November 08th 2017 - InflaRx, the biopharmaceutical company developing new therapeutics in the terminal complement space, today announced the pricing of its initial public offering of 6,667,000 common shares at an initial public offering price of $15.00 per common share, for total gross proceeds of approximately $100 million.
June 7th 2016 - InflaRx announced today that the first patient has been dosed preventively in a phase II clinical trial of IFX-1, a first-in-class monoclonal anti-complement C5a antibody, in patients undergoing complex cardiac surgery.
January 28th 2016: InflaRx announced today positive results from its SCIENS phase IIa clinical trial of IFX-1. The trial reached all primary endpoints by demonstrating safety, tolerability and biological proof of concept of IFX-1 in patients suffering from early septic organ dysfunction. IFX-1 highly statistically significantly reduced and effectively blocked C5a in a dose-dependent manner. In addition, the data showed positive trends in various other clinically relevant efficacy endpoints.
InflaRx appoints Arnd Christ as CFO starting June 2015. Arnd has a successful track record as CFO in various public and private biotech companies (Medigene AG, Novimmune SA, Probiodrug AG etc.) and will join the executive management board of the company.
InflaRx announces receipt of the clinical trial authorization of its phase I clinical trial program for IFX-1, investigating safety and tolerability in a double blinded placebo controlled dose escalation study.